AMS-17

• Description :

  AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD) [1][2].

• UNSPSC :

  12352005

• Target :

  NOD-like Receptor (NLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ams-17.html

• Purity :

  98.09

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1N(CCCN1S(=O)(C2=CC=C(C=C2)C(F)(F)F)=O)C3=CN=CN=C3

• Molecular Formula :

  C15H13F3N4O3S

• Molecular Weight :

  386.35

• References & Citations :

  [1]Zhang C, et al. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorg Med Chem.|[2]Akif A, et al. Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia. Fluids Barriers CNS. 2025 Jun 3;22 (1) :55.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NLRP3

• CAS Number :

  [3019885-78-7]